Differences between graft product and donor side effects following bone marrow or stem cell donation

G. Favre, M. Beksaç, A. Bacigalupo, T. Ruutu, A. Nagler, E. Gluckman, N. Russell, J. Apperley, J. Szer, K. Bradstock, A. Buzyn, J. Matcham, A. Gratwohl, N. Schmitz, H. Greinix, D. Niederwieser, D. Nachbauer, M. Boogaerts, A. Ferrant, R. ArnoldE. Gluckman, N. C. Gorin, N. Frickhofen, N. Schmitz, A. Zander, S. McCann, A. Nagler, A. Bacigalupo, A. Gratwohl, J. Apperley, N. H. Russell, O. Ringdén, I. Majolino, J. P. Jouet, B. Varet, J. Finke, G. Smith, A. Bosi, G. Lambertenghi-Deliliers, K. Kolbe, T. Ruutu, K. A. Bradstock, B. Lioure, T. Hughes, J. Szer, R. Herrmann, L. Trümper, M. Falda, M. Beksaç, E. Nikiforakis, M. Abecasis, J. Rowe, M. Potter, H. Wandt, R. Schwerdtfeger, J. Casper, A. Pagliuca

Research output: Contribution to journalArticlepeer-review

77 Citations (Scopus)


We report graft product stem cell yields and donor safety results of a randomized multicenter study comparing allogeneic peripheral blood stem cell (PBSC) PBSC transplantation with BM transplantation. Matched HLA-identical sibling donors (n = 329) were randomized to filgrastim-mobilized PBSC or bone marrow (BM) donation groups. Median yields per kg recipient weight of CD34+ cells, T cells, and natural killer (NK) cells, respectively, were approximately two-fold, eight-fold, and greater than eight-fold in the PBSC group than in the BM group (CD34+ cells, 5.8 × 106/kg vs 2.7 × 106/kg; T cells, 300.1 × 106/kg vs 35.7 × 106/kg; NK cells, 28.2 × 106/kg vs 3.6 × 106 /kg; P<0.001 for each). In connection with the cell collection procedures, PBSC donors spent a shorter median time in hospital than BM donors (0 vs 2 days; median difference -2 days, 95% CI -2 to 2) and had fewer median days of restricted activity (2 vs 6 days; median difference -3 days, 95% CI -4 to 2). Overall, 65% of PBSC donors and 57% of BM donors reported at least one adverse event (AE), most of which were transient, mild-moderate in severity, and without clinical sequelae. PBSC donors experienced predominantly filgrastim-related AEs, while BM donors experienced predominantly harvest-related AEs.

Original languageEnglish
Pages (from-to)873-880
Number of pages8
JournalBone Marrow Transplantation
Issue number9
Publication statusPublished or Issued - 14 Oct 2003


  • Allogeneic hematopoietic stem cell transplantation
  • Donor safety
  • Granulocyte colony-stimulating factor
  • Leukapheresis
  • Peripheral blood stem cells

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this